EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-80
SponsorDana-Farber Cancer Institute
About this trial
This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening.
The name of the test used in this research study is:
-Circulating free DNA (cfDNA) Assay
Eligibility criteria
Qualifiers
Non-tobacco using (currently)
Self-identify as East Asian (including Southeast Asian) or Hispanic/Latinx.
East Asian includes those who self-identify as Chinese, Japanese, Korean, Taiwanese, Malaysian
Southeast Asian includes those who self-identify as Cambodian, Thai, Vietnamese, Filipino
Disqualifiers
Having had a chest CT scan in the last 3 years or having an anticipated chest CT scan during the enrollment period.
Having a current cancer or history of cancer within the last 5 years, excluding localized non-melanoma skin cancer and breast ductal carcinoma in situ.
More than 400 lifetime cigarettes (i.e., 20 packs) of smoking or tobacco use
Adults unable to provide informed consent
Trial design
Treatments tested in this trial
- Circulating Tumor DNA (ctDNA) Assay
Treatment groups
1,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Dana-Farber Cancer Institute
Lead sponsor
Beth Israel Deaconess Medical Center
Collaborator
Boston Medical Center
Collaborator
Massachusetts General Hospital
Collaborator
Source ClinicalTrials.gov